Introduction Age and lymph node ratio have been attributed as independent predictors for survival and recurrence in carcinoma of unknown primary (CUP).
Objective The purpose of this study was to analyze the prognostic value of p16 overexpression for CUP in the absence of true primary (TP).
Methods The study involved 43 patients who underwent therapeutic lymph node dissection (LND) from 2000 to 2015 after all the diagnostic work up for CUP. Immunohistochemistry for p16 overexpression was performed. Cox proportional hazard regression analysis was used to analyze the prognostic impact on 5-year overall survival (OS) and recurrence-free survival (RFS).
Results The male-to-female ratio was 5.1:1, with a median age of 62 years. The clinicopathological data, except for p16 overexpression, did not differ significantly in terms of 5-year OS and RFS. The Cox regression analysis proposed p16 positivity to be an independent prognosticator of regional recurrence-free survival (RRFS) (hazard ratio [HR] 6.180, p = 0.21). The median time to recurrence and death were 10 and 25 months, respectively.
Conclusion Cervical metastasis with p16 overexpression is a significant prognostic factor of improved RFS after surgery in CUP. The prognostic significance of lymph node p16 positivity should be further studied.
Keywords unknown primary - neoplasm metastasis - head and neck neoplasms Ethics Approval and Consent to ParticipateEthical exemption was granted by the ethics committee of the Medical University of Vienna.
All data generated or analyzed during this study are included in this published article.
B. E. and S.G.: conceptualization; S. J., J. P.: methodology; N. S.: software; A. S., M. G.: validation; N. S.: formal analysis; S. G.: investigation; S. J.: resources; S. G., S.J.: data curation; M. F.: writing and original draft preparation, B. E., M. F., J. P.: writing, review and editing; G. H.: visualization; B. E.: supervision.
Publication HistoryReceived: 18 September 2021
Accepted: 22 August 2022
Article published online:
23 October 2023
© 2023. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Comments (0)